Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.

Roberta Loveikyte,Arno R Bourgonje, Johannes J van der Reijden,Marian L C Bulthuis,Lukas J A C Hawinkels,Marijn C Visschedijk,Eleonora A M Festen,Hendrik M van Dullemen,Rinse K Weersma,Harry van Goor,Andrea E van der Meulen-de Jong,Gerard Dijkstra

Inflammatory bowel diseases（2023）

引用 3|浏览24

暂无评分

摘要

Hepcidin levels in IBD are primarily determined by ID, even in an inflammatory state. In addition, induction therapy can decrease hepcidin levels, which might lead to better bioavailability of iron supplements. Therefore, hepcidin is a potential diagnostic ID biomarker that could assist therapeutic decision making.

查看译文

关键词

biomarkers,hepcidin,inflammatory bowel disease,iron deficiency,iron deficiency anemia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要